William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
- Aug 19, 2025
- 1 min read
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall Street disappointment. He describes whether he agrees with the reactions or not, and how the totality of the obesity market is shaping up.
.png){kind=logo}